Physician profile
Julie Settle
NPI 1003103847
$10,291.30
in general payments reported to CMS, 2019-2025
45 companies · $2,398 in 2025
The $2,398 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,323 · 2020: $1,696 · 2021: $735 · 2022: $621 · 2023: $973 · 2024: $1,544 · 2025: $2,398.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,915 · Education: $0.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,915.46 |
| Education | $0.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,339.62 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Pfizer INC. | $1,121.71 | 2019-2025 | |
| Lilly USA, LLC | $1,012.66 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $950.43 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Takeda Pharmaceuticals U.S.A., INC. | $701.92 | 2019-2025 | Trintellix |
| Abbvie INC. | $579.85 | 2020-2025 | Qulipta, Ubrelvy, Vraylar |
| Glaxosmithkline, LLC. | $534.51 | 2019-2025 | Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $403.72 | 2019-2024 | Jardiance |
| Allergan, INC. | $399.26 | 2019-2020 | |
| Daiichi Sankyo INC. | $311.83 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $302.11 | 2019-2024 | Vaxelis, Gardasil 9, Vaxneuvance |
| Axsome Therapeutics, INC. | $267.12 | 2024-2025 | Auvelity |
| Astellas Pharma US INC | $241.31 | 2019-2025 | Veozah |
| Otsuka America Pharmaceutical, INC. | $230.95 | 2019-2025 | Rexulti, Abilify Maintena |
| Abbott Laboratories | $220.68 | 2022-2025 | Freestyle Libre |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julie Settle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.